New diabetes shot UBT38006 enters first human safety trial
NCT ID NCT07630233
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a single injection of UBT38006 in 43 healthy adult men to see if it is safe and how the body processes it. Participants receive either the drug, a placebo, or an active comparator (insulin degludec). The goal is to gather safety data and measure drug levels in the blood, not yet to treat diabetes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
UBT38006 injection
What this could lead to
If successful, this could point toward a new, longer-acting diabetes treatment that requires fewer injections.
What could go wrong
This is a very early Phase 1 trial in only 43 healthy men, not people with diabetes. It primarily checks safety, not effectiveness, and many early-stage drugs fail to advance.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS (T2DM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••